FDA Approves Pivekimab Sunirine-pvzy for BPDCN

The Food and Drug Administration (FDA) has announced the approval of pivekimab sunirine-pvzy (Decnupaz) for the treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This new therapeutic option is a CD123-directed antibody and alkylating agent conjugate, specifically designed to target the unique markers of this ultra-rare hematologic malignancy.

The application was granted priority review, and the agent previously received both breakthrough and orphan drug designations to expedite its development for this serious condition.

Clinical evidence: The CADENZA trial

The efficacy of pivekimab sunirine-pvzy was established through CADENZA (NCT03386513), a multicenter, open-label, single-arm clinical trial. The study evaluated adult patients across two distinct cohorts: those with treatment-naïve BPDCN (N=33) and those with relapsed or refractory (R/R) BPDCN (N=51). Patients with evidence of active central nervous system disease were excluded from the trial.

The primary measure of efficacy was the rate of complete remission or clinical complete remission (CR/CRc). In the treatment-naïve group, the results were particularly robust:

• Response Rate: 69.7% (23/33 patients) achieved a CR/CRc (95% CI: 51.3, 84.4).
• Duration: The median duration of CR/CRc was 9.7 months (95% CI: 2.9, not estimable) with a median follow-up of 21.5 months.

For the R/R population, the therapy also showed activity, though at lower rates:

• Response Rate: 15.7% (8/51 patients) achieved a CR/CRc (95% CI: 7.0, 28.6).
• Duration: The median duration of CR/CRc was 9.2 months (Range: 2.7, 27.6+) with a median follow-up of 24.1 months.

Safety profile and nursing considerations

For oncology nurses, the safety profile of pivekimab sunirine-pvzy requires diligent monitoring. The prescribing information includes a Boxed Warning for hepatotoxicity, which includes the risk of hepatic veno-occlusive disease.

Additional warnings and precautions that nursing staff should be prepared to manage include:

• Infusion-related reactions
• Edema
• Sulfite allergic reactions
• Embryo-fetal toxicity

Healthcare professionals are encouraged to report all serious suspected adverse events to the FDA’s MedWatch Reporting System.

Administration and dosing

The recommended dosage for pivekimab sunirine-pvzy is 0.045 mg/kg, administered intravenously over approximately 15-30 minutes. This should be given once every three weeks (21-day cycle) until disease progression or unacceptable toxicity occurs.

It is essential for the nursing team to ensure the dose is calculated based on the patient's actual body weight for each cycle.

This approval represents a significant step forward in the management of BPDCN, providing a targeted therapy where options have historically been limited. The review process also utilized an Assessment Aid, a voluntary submission from the manufacturer to facilitate the FDA's thorough assessment of the drug’s benefit-risk profile.

Reference

1. U.S. Food and Drug Administration. FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy. May 27, 2026. Accessed May 27, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare